US biotech firm FibroGen (Nasdaq: FGEN) has appointed Enrique Conterno as the company’s chief executive and a member of the board of directors, effective immediately.
He replaces Thomas Neff, founder, and former CEO and chairman of FibroGen, who passed away unexpectedly in August last year.
Mr Conterno previously worked as a senior vice president for Eli Lilly (NYSE: LLY), serving as president, Lilly USA, president, Lilly Diabetes, and a member of Lilly’s corporate executive committee.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze